A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

The agreement encompasses development and commercial milestones for the products, which could amount to up to $180m.

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

such as adalimumab (Humira), golimumab (Simponi), and infliximab (Remicade) A medication called Janus kinase (JAK) inhibitors may also help reduce inflammation in certain types of arthritis.

in 2012 and J&J’s Simponi (golimumab) in 2013. In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Objective To evaluate golimumab's effect on MRI-detected spinal inflammation in ankylosing spondylitis (AS). Methods Patients were randomly assigned to subcutaneous injections of placebo (n=78), ...

Objective To evaluate radiographic progression in patients with ankylosing spondylitis (AS) receiving two different doses of the tumour necrosis factor antagonist golimumab. Methods 356 patients with ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Golimumab is given once every four weeks, subcutaneously, and also has an intravenous formulation. These intervals are changed, at times, with some of these agents, related to patient response. For ...